Compare THRY & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 191.1M |
| IPO Year | 2020 | 2001 |
| Metric | THRY | CGEN |
|---|---|---|
| Price | $4.18 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $9.33 | $5.00 |
| AVG Volume (30 Days) | ★ 584.0K | 411.7K |
| Earning Date | 04-30-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $37.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $1.30 |
| 52 Week High | $14.28 | $3.24 |
| Indicator | THRY | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 40.66 |
| Support Level | $3.14 | $1.98 |
| Resistance Level | $6.27 | $2.35 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 98.80 | 65.82 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.